Immunoglobulin Light Chain Deposition: Clinical Trials

1 trial for Immunoglobulin Light Chain Deposition, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 withdrawn. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Withdrawn 1

Follow Immunoglobulin Light Chain Deposition: new trials by email Literature Review of Immunoglobulin Light Chain Deposition trials Research Report on Immunoglobulin Light Chain Deposition

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
Bortezomib, Dexamethasone, Ibrutinib - Amyloidosis, Immunoglobulin Light Chain Deposition
Phase 2WithdrawnMayo Clinic2018-03-152018-03-02

Narrower conditions

Amyloidosis (1)

Broader conditions

Metabolic Diseases (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Proteostasis Deficiencies (1)

Interventions

Bortezomib (1)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  auricularum (1)  ·  dexamethasone 21-phosphate (1)  ·  dexamethasone acetate (1)  ·  ibrutinib (1)

Sponsors

Mayo Clinic (1)

Top investigators

Taimur Sher (1)

NIH funding

P30CA015083 (1)